Vertex Pharmaceuticals (VRTX) Assets Average (2016 - 2025)
Vertex Pharmaceuticals has reported Assets Average over the past 16 years, most recently at $25.3 billion for Q4 2025.
- Quarterly results put Assets Average at $25.3 billion for Q4 2025, up 12.8% from a year ago — trailing twelve months through Dec 2025 was $25.3 billion (up 12.8% YoY), and the annual figure for FY2025 was $24.1 billion, up 6.44%.
- Assets Average for Q4 2025 was $25.3 billion at Vertex Pharmaceuticals, up from $24.4 billion in the prior quarter.
- Over the last five years, Assets Average for VRTX hit a ceiling of $25.3 billion in Q4 2025 and a floor of $11.9 billion in Q1 2021.
- Median Assets Average over the past 5 years was $20.3 billion (2023), compared with a mean of $18.9 billion.
- Biggest five-year swings in Assets Average: surged 38.67% in 2021 and later dropped 2.65% in 2025.
- Vertex Pharmaceuticals' Assets Average stood at $13.0 billion in 2021, then soared by 33.8% to $17.4 billion in 2022, then increased by 27.54% to $22.2 billion in 2023, then rose by 0.71% to $22.4 billion in 2024, then rose by 12.8% to $25.3 billion in 2025.
- The last three reported values for Assets Average were $25.3 billion (Q4 2025), $24.4 billion (Q3 2025), and $23.5 billion (Q2 2025) per Business Quant data.